South Korea’s Celltrion (Kosdaq: 068270) saw its share rise 1.82% to 195,500 won after it revealed it has agreed to partner for the development of novel ADCs against validated antibody targets, including HER21 and CD202 with Canada-based iProgen Biotech.
No financial terms of the collaboration were revealed.
The terms of the partnership agreement include: (1) Celltrion manufactures and supplies four recombinant antibodies to iProgen, among which two are HER2 and CD20 targeting, selected by Celltrion, and two additional targets to be selected by iProgen, (2) Celltrion provides supports for the Chemistry, Manufacturing, and Control (CMC) activities for the investigational new drug (IND) application and the Phase-I clinical trial, (3) iProgen conducts the Phase-I clinical trial using these drug candidates, and (4) upon completion of Phase I, Celltrion has the right of first negotiation on these drug candidates for global in-licensing.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze